A follow-up Study of Effect of PDE5i Drugs on Extended High-frequency Hearing

Phosphodiesterase type 5 inhibitors (PDE5i), such as Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra), are commonly used to treat erectile dysfunction (ED) and other conditions like pulmonary hypertension and benign prostatic hyperplasia. While their therapeutic effects are well-documented, limited research exists on their potential ototoxicity. Some studies suggest that PDE5i drugs may impact hearing, potentially through the alteration of the nitric oxide pathway, which is crucial for cochlear function. Extended High-frequency audiometry (EHFA) has proven sensitive in detecting ototoxicity, making it a valuable tool for evaluating drug-induced hearing loss.The study involved 60 participants, 30 in the observational group (PDE5i users) and 30 in the control group (healthy individuals). Pre- and post-medication EHFA revealed that the observational group had significantly poorer hearing thresholds than the control group both before and after taking PDE5i drugs. The results showed that the pre-medication hearing thresholds of the observational group were already impaired, suggesting a pre-existing sensitivity to hearing loss. Post-medication, there was further deterioration in hearing thresholds.The study found that PDE5i users exhibited significantly poorer hearing sensitivity, even before taking the medication, possibly due to underlying hearing issues associated with erectile dysfunction. While the findings indicate potential ototoxic effects, further research is needed to confirm these results and explore the long-term impact. Close monitoring of hearing sensitivity in PDE5i users is recommended.